NICE advises on sunitinib in renal cell carcinoma

NICE has issued criteria that should be met before the use of sunitinib should be considered.

The guidance states that sunitinib may be used as first-line therapy in people with advanced and/or metastatic renal cell carcinoma who are suitable for immunotherapy and have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

The guidance also states that people who are currently being treated with sunitinib for advanced and/or metastatic renal cell carcinoma but who do not meet these criteria should have the option to continue their therapy until they and their clinicians consider it appropriate to stop.

A summary of the new guidance is available at To read the full guidance visit the NICE website.


Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases